Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019;14(3):233-237.
doi: 10.2174/1574886314666190522094713.

Panitumumab Induced Forearm Panniculitis in Two Women With Metastatic Colon Cancer

Ciliberto Domenico  1 , Ierardi Antonella  1 , Caroleo Benedetto  1 , Scalise Luigi  1 , Cimellaro Antonio  1 , Colangelo Lidia  1 , Spaziano Giuseppe  2 , Luca Gallelli  3
Affiliations
Case Reports

Panitumumab Induced Forearm Panniculitis in Two Women With Metastatic Colon Cancer

Ciliberto Domenico et al. Curr Drug Saf. 2019.

Abstract

Background: Panitumumab is an EGFR inhibitor used for the treatment of metastatic colorectal cancer (mCRC), even if its use is related to skin toxicity.

Case presentation: We report the development of forearm panniculitis in two women during the treatment with Panitumumab (6 mg/Kg intravenous every 2 weeks) + FOLFOX-6 (leucovorin, 5- fluorouracil, and oxaliplatin at higher dosage) for the treatment of mCRC.

Results: In both patients, clinical, laboratory and radiological evaluation documented the presence of a local panniculitis, probably related to panitumumab (Naranjo score: 6). Panatimumab discontinuation and antimicrobial + corticosteroid treatment induced a remission of skin manifestations.

Conclusion: We reported for the first time the development of panniculitis during Panitumumab treatment, and we documented that the treatment with beta-lactams to either fluoroquinolones or oxazolidinone in the presence of corticosteroid improves clinical symptoms in young patients with mCRC, without the development of adverse drug reactions or drug-drug interactions.

Keywords: EGFR; FOLFOX; Panitumumab; adverse drug reaction; mCRC; panniculitis..

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Panniculitis in the first woman at the admission. It is possible to see the presence of a large area of erythema and lymphangitis.
Fig. (2)
Fig. (2)
Ultrasound of the forearm: it is possible to note inhomogeneity of the sub-cutis with tissue edema and marked structural disruption of the subcutaneous adipose panniculus.
Fig. (3)
Fig. (3)
Magnetic resonance: thickened of sub-cutis and structural disruption of the subcutaneous adipose panniculus.
Fig. (4)
Fig. (4)
Panniculitis in the second woman at the admission. It is possible to see the large area of erythema and olecranon bursitis at admission.
See this image and copyright information in PMC

References

    1. Ra H.S., Shin S.J., Kim J.H., Lim H., Cho B.C., Roh M.R. The impact of dermatological toxicities of anti-cancer therapy on the dermatological quality of life of cancer patients. J. Eur. Acad. Dermatol. Venereol. 2013;27(1):e53–e59. - PubMed
    1. Rosen A.C., Case E.C., Dusza S.W., et al. Impact of dermatologic adverse events on quality of life in 283 cancer patients: A questionnaire study in a dermatology referral clinic. Am. J. Clin. Dermatol. 2013;14(4):327–333. - PubMed
    1. Thaler J., Karthaus M., Mineur L., et al. Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study. BMC Cancer. 2012;12:438. - PMC - PubMed
    1. Douillard J.Y., Oliner K.S., Siena S., et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 2013;369(11):1023–1034. - PubMed
    1. Schwartzberg L.S., Rivera F., Karthaus M., et al. PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J. Clin. Oncol. 2014;32(21):2240–2247. - PubMed

Publication types

MeSH terms

Supplementary concepts